Dog Canine Atopic Dermatitis Treatment Options

Atopic dermatitis is chronic allergic skin disease affecting up to 15% of dogs, and new targeted biologics have revolutionized management by providing itch control without immunosuppression.

Key Facts

Canine atopic dermatitis (CAD) affects 10-15% of the global dog population
It results from immune dysregulation and epidermal barrier defects allowing allergen penetration
Secondary skin infections with bacteria and yeast worsen the cycle
Traditional treatments including steroids caused side effects limiting long-term use
Oclacitinib (Apoquel) blocks the JAK-STAT pathway reducing itch within 24 hours
Lokivetmab (Cytopoint) is a monoclonal antibody targeting IL-31, providing month-long itch control
Allergen immunotherapy (ASIT) can desensitize 50-80% of dogs to specific allergens
Regular bathing with veterinary shampoos strengthens skin barrier function

Welfare Considerations

Chronic itch is one of the most distressing conditions in companion animal medicine. Dogs with uncontrolled atopic dermatitis scratch, chew, and rub affected areas constantly, disrupting sleep and normal activity. Secondary infections cause additional pain and discomfort. The development of targeted biologics like Cytopoint and Apoquel has been genuinely transformative for welfare - providing effective itch control without the side effects of steroids. Every dog with uncontrolled atopy represents an avoidable welfare burden given current treatment options.

What You Can Do

Seek referral to a veterinary dermatologist for dogs with uncontrolled atopic dermatitis
Ask your vet about Apoquel or Cytopoint as targeted itch control options
Consider allergy testing and immunotherapy for long-term management
Implement regular bathing with veterinary shampoos to strengthen skin barrier
Support veterinary dermatology research into new atopy treatments